Rapid weight regain occurs after discontinuation of semaglutide or tirzepatideWeight returns quickly after stopping semaglutide or tirzepatide medications

This meta-analysis evaluated the weight-regain trajectories of 1,776 participants who underwent treatment with either semaglutide or tirzepatide and subsequently discontinued the medication. The study focused on the dynamics of weight regain over a follow-up period of 4 to 52 weeks. The primary objective was to characterize the speed and magnitude of weight regain following the cessation of these GLP-1 and GIP receptor agonists.

At the point of cessation, participants had achieved a mean weight loss of 15.35 kg (95% CrI 11.18-19.60). Following discontinuation, the analysis identified a mean monthly regain rate of 1.04 kg/month (95% CrI 0.80-1.29). The median time to regain 50% of the lost weight was 7.50 months (95% CrI 5.05-10.57). The median time to return to the patient's baseline weight was 15.00 months (95% CrI 10.10-21.13).

Regarding drug-specific differences, the analysis found no clear independent drug-specific difference in regain rates between tirzepatide and semaglutide after adjustment. While tirzepatide showed numerically faster regain than semaglutide in unadjusted analyses, these differences were not statistically significant after adjustment. The study also examined the impact of initial weight loss on regain speed, finding a strong directional association with faster regain, although the credible interval included zero. Additionally, the inclusion of behavioral or lifestyle support was directionally associated with slower regain, though the estimate for this specific intervention was imprecise.

Safety and tolerability data, including specific adverse event rates or reasons for discontinuation, were not reported. The study notes that while the data provides a clear trajectory for weight regain, the estimates beyond 52 weeks are model-based extrapolations and should be interpreted with caution.

These findings contribute to the understanding of long-term management for patients on incretin mimetics. While prior evidence has established the efficacy of these agents in reducing weight and improving metabolic markers, this analysis highlights the rapid and clinically meaningful nature of weight regain once therapy is stopped. The results suggest that the duration of weight loss is highly dependent on continued medication adherence.

Methodological limitations include the fact that data beyond 52 weeks were extrapolated using models. Furthermore, the imprecise nature of the estimate for behavioral support limits the ability to quantify the exact impact of lifestyle interventions on slowing regain.

Clinically, these results imply that patients must be counseled on the likelihood of rapid weight regain upon stopping semaglutide or tirzepatide. Practitioners may need to develop proactive maintenance plans or transition patients to alternative long-term management strategies before discontinuation occurs. Questions remain regarding the optimal duration of treatment required to stabilize weight and the specific intensity of behavioral interventions needed to mitigate the observed regain rates.